Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 394

1.

Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia.

de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJ, van Der Poll T.

Blood. 2000 Feb 15;95(4):1124-9.

2.

Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia.

de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJ, van der Poll T.

J Infect Dis. 2001 Jun 15;183(12):1815-8.

PMID:
11372037
3.

Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia.

de Kruif MD, Lemaire LC, Giebelen IA, van Zoelen MA, Pater JM, van den Pangaart PS, Groot AP, de Vos AF, Elliott PJ, Meijers JC, Levi M, van der Poll T.

J Immunol. 2007 Feb 1;178(3):1845-51.

4.

Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia.

de Pont AC, Moons AH, de Jonge E, Meijers JC, Vlasuk GP, Rote WE, Büller HR, van der Poll T, Levi M.

J Thromb Haemost. 2004 Jan;2(1):65-70.

5.

Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans.

Jilma B, Marsik C, Mayr F, Graninger MT, Taylor FB Jr, Ribel MC, Erhardtsen E, Handler S, Eichler HG.

Clin Pharmacol Ther. 2002 Oct;72(4):403-10.

PMID:
12386642
6.

Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia.

Pajkrt D, Lerch PG, van der Poll T, Levi M, Illi M, Doran JE, Arnet B, van den Ende A, ten Cate JW, van Deventer SJ.

Thromb Haemost. 1997 Feb;77(2):303-7.

PMID:
9157586
7.

Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia.

Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van den Ende A, ten Cate JW, van Deventer SJ.

Blood. 1997 Apr 15;89(8):2701-5.

8.

Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades.

Biemond BJ, Levi M, Ten Cate H, Van der Poll T, Büller HR, Hack CE, Ten Cate JW.

Clin Sci (Lond). 1995 May;88(5):587-94.

PMID:
7614818
9.

Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23).

von der Möhlen MA, van Deventer SJ, Levi M, van den Ende B, Wedel NI, Nelson BJ, Friedmann N, ten Cate JW.

Blood. 1995 Jun 15;85(12):3437-43.

10.

Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia.

Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B.

Crit Care Med. 2004 May;32(5):1136-40. Erratum in: Crit Care Med. 2004 Aug;32(8):1813.

PMID:
15190963
11.

Heparin blunts endotoxin-induced coagulation activation.

Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B.

Circulation. 1999 Dec 21-28;100(25):2485-90.

12.

Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia.

Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B.

Clin Pharmacol Ther. 2006 Jan;79(1):23-34.

PMID:
16413239
13.

Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock.

Matyal R, Vin Y, Delude RL, Lee C, Creasey AA, Fink MP.

Intensive Care Med. 2001 Aug;27(8):1274-80.

PMID:
11511939
14.

The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia.

Spiel AO, Firbas C, Mayr FB, Leitner JM, Schmidt B, Knöbl P, Varadi K, Jilma B.

Thromb Haemost. 2005 Dec;94(6):1148-55.

PMID:
16411386
15.

Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation.

Choi G, Vlaar AP, Schouten M, Van't Veer C, van der Poll T, Levi M, Schultz MJ.

Eur Respir J. 2007 Sep;30(3):423-8.

16.

Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock.

Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun TC, Creasey AA, Hinshaw LB, et al.

Circ Shock. 1994 Nov;44(3):126-37.

PMID:
7600636
17.

Dobutamine does not influence inflammatory pathways during human endotoxemia.

Lemaire LC, de Kruif MD, Giebelen IA, Levi M, van der Poll T, Heesen M.

Crit Care Med. 2006 May;34(5):1365-71.

PMID:
16540959
18.

Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.

Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, Hack CE, Peppelenbosch MP, van der Poll T.

Blood. 2003 Jun 1;101(11):4446-8.

19.

Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia.

van der Poll T, Jansen PM, Montegut WJ, Braxton CC, Calvano SE, Stackpole SA, Smith SR, Swanson SW, Hack CE, Lowry SF, Moldawer LL.

J Immunol. 1997 Feb 15;158(4):1971-5.

PMID:
9029140
20.

The proinflammatory cytokine response to coagulation and endotoxin in whole blood.

Johnson K, Aarden L, Choi Y, De Groot E, Creasey A.

Blood. 1996 Jun 15;87(12):5051-60.

Items per page

Supplemental Content

Support Center